Drug maker Lupin today said its three of its 100 per cent subsidiaries, including Lupin Pharmacare, would merge with the parent company.
Lupin Pharmacare and Lupin Herbal, two wholly-owned subsidiaries of Lupin, have filed applications before the Bombay High Court, to amalgamate themselves with the company, the pharmaceuticals firm said in a filing to the Bombay Stock Exchange (BSE).
Further, another subsidiary of the company Novodigm will shortly be filing an application before the Ahmedabad High Court to amalgamate itself with Lupin, it said.
The appointed date of merger of these three firms is April 1, it added.
Shares of Lupin were trading at Rs 1145, up 2.16 per cent in the afternoon trade on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app